Abstract

Purpose: We evaluate the risk factors for nocturia in patients with chronic kidney disease, and determine whether the metabolic syndrome and its components aggravate nocturia in these patients. Materials and Methods: We enrolled patients with chronic kidney disease who had regular followup at nephrology clinics, and excluded from study those patients undergoing dialysis, and those with neurogenic bladder or active urinary tract infection. Patients were asked to complete a questionnaire including medical history, clinical parameters and times of nocturnal voids in the last month. Laboratory parameters were checked when the questionnaire was completed. Clinically significant nocturia was defined as voiding 2 or more times per night. The metabolic syndrome was defined according to the ATP III (National Cholesterol Education Program Adult Treatment Panel III) guidelines. Chronic kidney disease was divided into 5 stages (based on National Kidney Foundation guidelines). Multivariate logistic regression was used to evaluate the risk factors for clinically significant nocturia. Results: A total of 202 men and 234 women were eligible for analysis (mean age 68.4 years). The prevalence rate of clinically significant nocturia in patients with chronic kidney disease was 64.0%. Statistically significant risk factors for clinically significant nocturia were patient age (OR 1.02, 95% CI 1.003-1.04) and chronic kidney disease stage (OR 1.47, 95% CI 1.19-1.81) but not gender. Although 53.9% of our patients with chronic kidney disease had the metabolic syndrome, the metabolic syndrome (adjusted OR 0.96, 95% CI 0.64-1.44) and its components had no significant correlations with clinically significant nocturia. Conclusions: Clinically significant nocturia is prevalent in patients with chronic kidney disease, and the severity increased with chronic kidney disease stage and patient age. Contrary to previous reports, the metabolic syndrome did not increase the risk of clinically significant nocturia in patients with chronic kidney disease.

Original languageEnglish
Pages (from-to)2269-2273
Number of pages5
JournalJournal of Urology
Volume188
Issue number6
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Nocturia
Chronic Renal Insufficiency
Guidelines
Neurogenic Urinary Bladder
Nephrology
Urinary Tract Infections
Dialysis
Adenosine Triphosphate
Logistic Models
Cholesterol

Keywords

  • chronic
  • kidney failure
  • lower urinary tract symptoms
  • metabolic syndrome X
  • nocturia

ASJC Scopus subject areas

  • Urology

Cite this

Risks of nocturia in patients with chronic kidney disease - Do the metabolic syndrome and its components matter? / Wu, Mei Yi; Wu, Yi Lien; Hsu, Yung Ho; Lin, Yuh Feng; Fan, Yang Chih; Lin, Ying-Chin; Chang, Shang Jen.

In: Journal of Urology, Vol. 188, No. 6, 12.2012, p. 2269-2273.

Research output: Contribution to journalArticle

@article{37c96f7f4c1c45a799505d54294e29bc,
title = "Risks of nocturia in patients with chronic kidney disease - Do the metabolic syndrome and its components matter?",
abstract = "Purpose: We evaluate the risk factors for nocturia in patients with chronic kidney disease, and determine whether the metabolic syndrome and its components aggravate nocturia in these patients. Materials and Methods: We enrolled patients with chronic kidney disease who had regular followup at nephrology clinics, and excluded from study those patients undergoing dialysis, and those with neurogenic bladder or active urinary tract infection. Patients were asked to complete a questionnaire including medical history, clinical parameters and times of nocturnal voids in the last month. Laboratory parameters were checked when the questionnaire was completed. Clinically significant nocturia was defined as voiding 2 or more times per night. The metabolic syndrome was defined according to the ATP III (National Cholesterol Education Program Adult Treatment Panel III) guidelines. Chronic kidney disease was divided into 5 stages (based on National Kidney Foundation guidelines). Multivariate logistic regression was used to evaluate the risk factors for clinically significant nocturia. Results: A total of 202 men and 234 women were eligible for analysis (mean age 68.4 years). The prevalence rate of clinically significant nocturia in patients with chronic kidney disease was 64.0{\%}. Statistically significant risk factors for clinically significant nocturia were patient age (OR 1.02, 95{\%} CI 1.003-1.04) and chronic kidney disease stage (OR 1.47, 95{\%} CI 1.19-1.81) but not gender. Although 53.9{\%} of our patients with chronic kidney disease had the metabolic syndrome, the metabolic syndrome (adjusted OR 0.96, 95{\%} CI 0.64-1.44) and its components had no significant correlations with clinically significant nocturia. Conclusions: Clinically significant nocturia is prevalent in patients with chronic kidney disease, and the severity increased with chronic kidney disease stage and patient age. Contrary to previous reports, the metabolic syndrome did not increase the risk of clinically significant nocturia in patients with chronic kidney disease.",
keywords = "chronic, kidney failure, lower urinary tract symptoms, metabolic syndrome X, nocturia",
author = "Wu, {Mei Yi} and Wu, {Yi Lien} and Hsu, {Yung Ho} and Lin, {Yuh Feng} and Fan, {Yang Chih} and Ying-Chin Lin and Chang, {Shang Jen}",
year = "2012",
month = "12",
doi = "10.1016/j.juro.2012.08.008",
language = "English",
volume = "188",
pages = "2269--2273",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Risks of nocturia in patients with chronic kidney disease - Do the metabolic syndrome and its components matter?

AU - Wu, Mei Yi

AU - Wu, Yi Lien

AU - Hsu, Yung Ho

AU - Lin, Yuh Feng

AU - Fan, Yang Chih

AU - Lin, Ying-Chin

AU - Chang, Shang Jen

PY - 2012/12

Y1 - 2012/12

N2 - Purpose: We evaluate the risk factors for nocturia in patients with chronic kidney disease, and determine whether the metabolic syndrome and its components aggravate nocturia in these patients. Materials and Methods: We enrolled patients with chronic kidney disease who had regular followup at nephrology clinics, and excluded from study those patients undergoing dialysis, and those with neurogenic bladder or active urinary tract infection. Patients were asked to complete a questionnaire including medical history, clinical parameters and times of nocturnal voids in the last month. Laboratory parameters were checked when the questionnaire was completed. Clinically significant nocturia was defined as voiding 2 or more times per night. The metabolic syndrome was defined according to the ATP III (National Cholesterol Education Program Adult Treatment Panel III) guidelines. Chronic kidney disease was divided into 5 stages (based on National Kidney Foundation guidelines). Multivariate logistic regression was used to evaluate the risk factors for clinically significant nocturia. Results: A total of 202 men and 234 women were eligible for analysis (mean age 68.4 years). The prevalence rate of clinically significant nocturia in patients with chronic kidney disease was 64.0%. Statistically significant risk factors for clinically significant nocturia were patient age (OR 1.02, 95% CI 1.003-1.04) and chronic kidney disease stage (OR 1.47, 95% CI 1.19-1.81) but not gender. Although 53.9% of our patients with chronic kidney disease had the metabolic syndrome, the metabolic syndrome (adjusted OR 0.96, 95% CI 0.64-1.44) and its components had no significant correlations with clinically significant nocturia. Conclusions: Clinically significant nocturia is prevalent in patients with chronic kidney disease, and the severity increased with chronic kidney disease stage and patient age. Contrary to previous reports, the metabolic syndrome did not increase the risk of clinically significant nocturia in patients with chronic kidney disease.

AB - Purpose: We evaluate the risk factors for nocturia in patients with chronic kidney disease, and determine whether the metabolic syndrome and its components aggravate nocturia in these patients. Materials and Methods: We enrolled patients with chronic kidney disease who had regular followup at nephrology clinics, and excluded from study those patients undergoing dialysis, and those with neurogenic bladder or active urinary tract infection. Patients were asked to complete a questionnaire including medical history, clinical parameters and times of nocturnal voids in the last month. Laboratory parameters were checked when the questionnaire was completed. Clinically significant nocturia was defined as voiding 2 or more times per night. The metabolic syndrome was defined according to the ATP III (National Cholesterol Education Program Adult Treatment Panel III) guidelines. Chronic kidney disease was divided into 5 stages (based on National Kidney Foundation guidelines). Multivariate logistic regression was used to evaluate the risk factors for clinically significant nocturia. Results: A total of 202 men and 234 women were eligible for analysis (mean age 68.4 years). The prevalence rate of clinically significant nocturia in patients with chronic kidney disease was 64.0%. Statistically significant risk factors for clinically significant nocturia were patient age (OR 1.02, 95% CI 1.003-1.04) and chronic kidney disease stage (OR 1.47, 95% CI 1.19-1.81) but not gender. Although 53.9% of our patients with chronic kidney disease had the metabolic syndrome, the metabolic syndrome (adjusted OR 0.96, 95% CI 0.64-1.44) and its components had no significant correlations with clinically significant nocturia. Conclusions: Clinically significant nocturia is prevalent in patients with chronic kidney disease, and the severity increased with chronic kidney disease stage and patient age. Contrary to previous reports, the metabolic syndrome did not increase the risk of clinically significant nocturia in patients with chronic kidney disease.

KW - chronic

KW - kidney failure

KW - lower urinary tract symptoms

KW - metabolic syndrome X

KW - nocturia

UR - http://www.scopus.com/inward/record.url?scp=84869082975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869082975&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2012.08.008

DO - 10.1016/j.juro.2012.08.008

M3 - Article

C2 - 23083649

AN - SCOPUS:84869082975

VL - 188

SP - 2269

EP - 2273

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -